Product-led growth: a case study playbook for healthcare and life sciences in the United Kingdom

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the United Kingdom. In this market, UK buyers reward understatement, credible references, and a pitch that respects their time, so the way you install product-led growth has to be shaped to that reality from day one.

Names removed, numbers preserved. This is a real product-led growth engagement, reproduced as a playbook. Client had product-market fit, a rev team of eleven, and a stalled pipeline.

Week one: diagnosis. The stated problem was "not enough leads". The actual problem was bolting PLG onto a product that requires a demo to understand, which had been masked by inbound velocity that peaked two quarters earlier.

Weeks two to three: rebuild the target list from scratch and re-cut the trigger. Product-led growth works when CAC collapses when the product qualifies for you; the client had drifted away from that first principle.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the United Kingdom it is compounded by the fact that credibility and reference base, not tooling is what actually gates growth. Product-led growth is only useful here when it is pointed at both constraints at once.

Weeks four to six: live at 20% of previous volume, quality bar raised. Self-serve activation to paid conversion moved every week, though absolute numbers stayed modest.

Weeks seven to twelve: ramp. By week ten the number was ahead of the pre-stall baseline. By week twelve it was 40% ahead. Cost per outcome was roughly halved.

What we would repeat: the diagnosis step, the quality bar, and the weekly review. What we would kill sooner: two tools we bought in month one that added noise instead of leverage.

The client's own summary at the end of quarter one: "we thought we needed more of everything; we actually needed less of the wrong things." That is usually the lesson.

Concretely for healthcare and life sciences in the United Kingdom: the healthcare teams that install this get past procurement instead of dying in it, and a single London-anchored win reshapes an entire year of UK pipeline. That is the reason it is worth installing product-led growth deliberately for this market rather than importing a playbook designed for somewhere else.